



NDA 208845/S-019

## **SUPPLEMENT APPROVAL**

Pacira Pharmaceuticals, Inc.  
Attention: Laurel Konkol  
Sr. Director Regulatory CMC  
5 Sylvan Way, Suite 300  
Parsippany, NJ 07054

Dear Laurel Konkol:

Please refer to your Supplemental New Drug Application (sNDA) dated and received March 7, 2024, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for ZILRETTA (triamcinolone acetonide extended release injectable suspension).

This “Changes Being Effectuated” supplemental new drug application provides for the following changes:

1. revision to section ‘11 Description’ in Prescribing Information (PI) to include NaOH and HCl as pH adjusters.
2. addition of identity of hydrochloric acid (HCl) and sodium hydroxide (NaOH) as pH adjusters for the Diluent in module 3.2.P.1 (Diluent).
3. inclusion of the specific gravity of the diluent in the composition table in 3.2.P.1 (Diluent) for clarity.

### **APPROVAL & LABELING**

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Teicher Agosto, Regulatory Business Process Manager, at (240) 402 - 3777.

Sincerely,

*{See appended electronic signature page}*

Gurpreet Gill-Sangha, Ph.D.  
Supervisor  
Division of Product Quality Assessment II  
Office of Product Quality Assessment I  
Office of Pharmaceutical Quality  
Center for Drug Evaluation and Research

Enclosure(s):

Content of Labeling



Gurpreet  
Gill Sangha

Digitally signed by Gurpreet Gill Sangha

Date: 9/05/2024 12:20:22PM

GUID: 5135f2ad000117842392c50c36c7f28a